G
Gabriel N. Hortobagyi
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1415
Citations - 115570
Gabriel N. Hortobagyi is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 166, co-authored 1374 publications receiving 104845 citations. Previous affiliations of Gabriel N. Hortobagyi include University of Texas System & University of Texas Medical Branch.
Papers
More filters
Journal ArticleDOI
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Roman Rouzier,Charles M. Perou,W. Fraser Symmans,Nuhad K. Ibrahim,Massimo Cristofanilli,Keith Anderson,Kenneth R. Hess,James Stec,James Stec,Mark Ayers,Peter Wagner,Paolo Morandi,Chang Fan,Islam Rabiul,Jeffrey S. Ross,Gabriel N. Hortobagyi,Lajos Pusztai +16 more
TL;DR: The basal-like and erbB2+ subtypes of breast cancer are more sensitive to paclitaxel- and doxorubicin-containing preoperative chemotherapy than the luminal and normal-like cancers.
Journal ArticleDOI
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Yoichi Nagata,Keng-Hsueh Lan,Xiaoyan Zhou,Ming Tan,Francisco J. Esteva,Aysegul A. Sahin,Kristine S. Klos,Ping Li,Brett P. Monia,Nina T. Nguyen,Gabriel N. Hortobagyi,Mien Chie Hung,Dihua Yu +12 more
TL;DR: In this paper, PTEN activation contributes to trastuzumab's antitumor activity and PI3K inhibitors rescued PTEN loss-induced trastusumab resistance.
Journal ArticleDOI
Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation
TL;DR: Demographic changes in the United States will result in a marked increase in the number of cancer diagnoses over the next 20 years, and continued efforts are needed to improve cancer care for older adults and minorities.
Journal ArticleDOI
Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy
Henry Mark Kuerer,Lisa A. Newman,Terry L. Smith,Fred C. Ames,Kelly K. Hunt,Kapil Dhingra,Richard L. Theriault,Gurpreet Singh,Susan M. Binkley,Nour Sneige,Thomas A. Buchholz,Merrick I. Ross,Marsha D. McNeese,Aman U. Buzdar,Gabriel N. Hortobagyi,S. Eva Singletary +15 more
TL;DR: Neoadjuvant chemotherapy has the capacity to completely clear the breast and axillary lymph nodes of invasive tumor before surgery and patients with LABC who have a pCR in the breastand axillary nodes have a significantly improved disease-free survival rate.
Journal ArticleDOI
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobagyi,Salomon M. Stemmer,Howard A. Burris,Yoon Sim Yap,Gabe S. Sonke,Shani Paluch-Shimon,Mario Campone,Kimberly L. Blackwell,Fabrice Andre,Eric P. Winer,Wolfgang Janni,Sunil Verma,Pierfranco Conte,Carlos L. Arteaga,David Cameron,Katarína Petráková,Lowell L. Hart,Cristian Villanueva,A. Chan,Erik Jakobsen,Arnd Nusch,Olga Burdaeva,Eva-Maria Grischke,Emilio Alba,Erik Wist,Norbert Marschner,Anne Favret,Denise A. Yardley,Thomas Bachelot,Ling-Ming Tseng,Sibel Blau,Fengjuan Xuan,Farida Souami,Michelle Miller,C. Germa,Samit Hirawat,Joyce O'Shaughnessy +36 more
TL;DR: Among patients receiving initial systemic treatment for HR-positive, HER2-negative advanced breast cancer, the duration of progression-free survival was significantly longer among those receiving ribociclib plus letrozole than among those received placebo plus let rozole, with a higher rate of myelosuppression in the ribocIClib group.